Immunogenicity and protection effects of cationic liposome containing imiquimod adjuvant on leishmaniasis in BALB/c mice

سال انتشار: 1398
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 419

فایل این مقاله در 10 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJBMS-22-8_012

تاریخ نمایه سازی: 20 مهر 1398

چکیده مقاله:

Objective(s): Protection against leishmaniasis, in the murine model, is dependent on developing a potent CD4+ mediated Th1 type response. Liposomes can be applied as immunoadjuvants to stimulate immune responses to different antigens. In the present study, it was investigated whether DOTAP liposomes having SLA and imiquimod adjuvant, can induce a Th1 response and protect against Leishmania major challenge in BALB/c mice. Materials and Methods: Liposomes were provided applying the lipid film procedure. BALB/C mice were subcutaneously immunized, three times with 2-week intervals, with various formulations. Assessment of lesion development and parasite burden in the foot and spleen after challenge with L. major, assessment of Th1 cytokine (IFN-γ), and titration of IgG isotypes assessed the type of generated immune reaction and the protection extent. Results: The mice immunized with Liposome DOTAP+imiquimod+SLA showed smaller footpad swelling which was meaningfully different (P<0.05) compared with other groups. The highest level of IgG2a was observed with Lip DOTAP+imiquimod+SLA more than the control (P<0.001). Mice immunized with Lip DOTAP+SLA+imiquimod demonstrated the least number of live parasites in the footpad and spleen. Cytokine assay showed that the greatest IFN- γ secretion was seen in the splenocytes of mice immunized with all formulations as compared to the control group (P<0.0001). In contrast, the lowest IL-4 production was detectable in Lip+imiquimod+SLA spleen, which was not significantly different compared with other groups.Conclusion: The results of this study show that liposome DOTAP+SLA+imiquimod formulation generates a cellular immune response that is protective against challenge against L. major.

نویسندگان

Ahmad Mehravaran

Infectious Diseases and Tropical Medicine Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran|Department of Parasitology and Mycology, Faculty of Medicine, Zahedan University of Medical Sciences,

Maryam Rezaei Nasab

Department of Parasitology and Mycology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

Hadi Mirahmadi

Infectious Diseases and Tropical Medicine Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran|Department of Parasitology and Mycology, Faculty of Medicine, Zahedan University of Medical Sciences,

Iraj Sharifi

Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, ...
  • Soto M, Ramírez L, Pineda MA, González VM, Entringer PF, ...
  • Evans KJ, Kedzierski L. Development of vaccines against visceral leishmaniasis. ...
  • Badiee A, Shargh VH, Khamesipour A, Jaafari MR. Micro/nanoparticle adjuvants ...
  • Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasseri K, ...
  • Raman VS, Duthie MS, Fox CB, Matlashewski G, Reed SG. ...
  • Noazin S, Modabber F, Khamesipour A, Smith PG, Moulton LH, ...
  • Belkaid Y, Von Stebut E, Mendez S, Lira R, Caler ...
  • Müller I, Kropf P, Louis JA, Milon G. Expansion of ...
  • von Stebut E, Udey MC. Requirements for Th1-dependent immunity against ...
  • Nordly P, Agger EM, Andersen P, Nielsen HM, Foged C. ...
  • Moon JJ, Suh H, Bershteyn A, Stephan MT, Liu H, ...
  • Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for ...
  • Mehravaran A, Jaafari MR, Jalali SA, Khamesipour A, Tafaghodi M, ...
  • Mazumder S, Maji M, Ali N. Potentiating effects of MPL ...
  • Joshi MD, Unger WJ, Storm G, van Kooyk Y, Mastrobattista ...
  • Smith DM, Simon JK, Baker Jr JR. Applications of nanotechnology ...
  • Krishnan L, Sad S, Patel GB, Sprott GD. Archaeosomes induce ...
  • Mehravaran A, Jaafari MR, Jalali SA, Khamesipour A, Tafaghodi M, ...
  • Mehravaran A, Jaafari MR, Jalali SA, Khamesipour A, Ranjbar R, ...
  • O’Hagan DT, Singh M. Microparticles as vaccine adjuvants and delivery ...
  • Alving CR. Liposomal vaccines: clinical status and immunological presentation for ...
  • Alving CR, Peachman KK, Rao M, Reed SG. Adjuvants for ...
  • Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve ...
  • Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F. ...
  • Alimohammadian MH, Hakimi H, Nikseresht M. The preparation and evaluation ...
  • Scott P, Pearce E, Natovitz P, Sher A. Vaccination against ...
  • Johnston D, Bystryn J-C. Topical imiquimod is a potent adjuvant ...
  • Bainor A, Chang L, McQuade TJ, Webb B, Gestwicki JE. ...
  • Torchilin V, Weissig V. Liposomes: a practical approach: Oxford University ...
  • Taswell C. Limiting dilution assays for the determination of immunocompetent ...
  • Titus RG, Marchand M, Boon T, Louis J. A limiting ...
  • Badiee A, Jaafari MR, Khamesipour A. Leishmania major: immune response ...
  • Jaafari MR, Badiee A, Khamesipour A, Samiei A, Soroush D, ...
  • Golali E, Jaafari MR, Khamesipour A, Abbasi A, Saberi Z, ...
  • Hejazi H, Tasbihi M, Jaafari M, Badiee A, Pestechian N, ...
  • Vanloubbeeck Y, Jones DE. The immunology of Leishmania infection and ...
  • Bal SM, Hortensius S, Ding Z, Jiskoot W, Bouwstra JA. ...
  • Elamanchili P, Lutsiak CM, Hamdy S, Diwan M, Samuel J. ...
  • Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A. ...
  • Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, ...
  • Bhowmick S, Ravindran R, Ali N. Leishmanial antigens in liposomes ...
  • Firouzmand H, Badiee A, Khamesipour A, Shargh VH, Alavizadeh SH, ...
  • Copland MJ, Rades T, Davies NM, Baird MA. Lipid based ...
  • Nobs L, Buchegger F, Gurny R, Allémann E. Current methods ...
  • Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat ...
  • Badiee A, Jaafari MR, Khamesipour A, Samiei A, Soroush D, ...
  • Korsholm KS, Andersen PL, Christensen D. Cationic liposomal vaccine adjuvants ...
  • Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, ...
  • Maji M, Mazumder S, Bhattacharya S, Choudhury ST, Sabur A, ...
  • Reiter MJ, Testerman TL, Miller RL, Weeks CE, Tomai MA. ...
  • Tomai MA, Gibson SJ, Imbertson LM, Miller RL, Myhre PE, ...
  • Mehravaran A, Rezaei Nasab M, Mirahmadi H, Sharifi I, Alijani ...
  • Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the ...
  • Iwasake A, Medzhitov R. Toll-like receptor control of the adaptive ...
  • Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev ...
  • Wickelgren I. Targeting the tolls. Science 2006; 312:184-187. ...
  • Zhang W-W, Matlashewski G. Immunization with a Toll-like receptor 7 ...
  • Othoro C, Johnston D, Lee R, Soverow J, Bystryn J-C, ...
  • نمایش کامل مراجع